At a glance
- Originator Roche
- Class Antineoplastics; Piperidines; Pyrimidines; Small molecules
- Mechanism of Action Apoptosis stimulants; CDC2 protein kinase inhibitors; Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 04 Mar 2010 Discontinued - Phase-I for Solid tumours in USA (IV)
- 04 Mar 2010 No development reported - Phase-I for Solid tumours in USA (IV)
- 01 Dec 2006 Data presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2006) added to the adverse events, pharmacokinetics and Cancer therapeutic trials sections